This article is more than 5 years old. Information may no longer be current.
Atezolizumab plus chemotherapy improves PFS, not OS, in non-small cell lung cancer
Click Here to Manage Email Alerts
A phase 3 trial designed to assess the addition of atezolizumab to chemotherapy as first-line treatment for patients with advanced nonsquamous non-small cell lung cancer met its coprimary endpoint of PFS, according to the agent’s manufacturer.
However, the other coprimary endpoint of OS has not yet been met.
The multicenter, double-blind IMpower132 study included 578 chemotherapy-naive patients with advanced nonsquamous NSCLC.
Researchers assigned half of the patients to atezolizumab (Tecentriq, Genentech) — a PD-L1 monoclonal antibody — plus cisplatin or carboplatin and pemetrexed. The other patients received chemotherapy alone.
Investigator-assessed PFS using RECIST v1.1 and OS in the intention-to-treat population served as coprimary endpoints.
The study met its PFS endpoint.
Researchers reported a numerical improvement in OS with the combination, but the difference did not reach statistical significance. Final OS results are expected next year.
“The IMpower132 study showed Tecentriq plus chemotherapy prolonged the time people with this type of advanced lung cancer lived without their disease worsening. We will discuss these results with health authorities,” Sandra Horning, MD, chief medical officer and head of global product development at Genentech, said in a company-issued press release.
Atezolizumab already is approved for the treatment of certain patients with urothelial carcinoma, as well as for patients with NSCLC whose disease progressed during or after platinum-containing chemotherapy.